1. Home
  2. LOOP vs NXTC Comparison

LOOP vs NXTC Comparison

Compare LOOP & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$1.02

Market Cap

58.1M

Sector

Industrials

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$13.27

Market Cap

46.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOOP
NXTC
Founded
2010
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
46.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LOOP
NXTC
Price
$1.02
$13.27
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
73.4K
37.5K
Earning Date
01-15-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,112,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$41.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10901.98
N/A
52 Week Low
$0.85
$2.69
52 Week High
$2.29
$15.74

Technical Indicators

Market Signals
Indicator
LOOP
NXTC
Relative Strength Index (RSI) 49.93 60.51
Support Level $0.95 $12.79
Resistance Level $1.04 $14.65
Average True Range (ATR) 0.07 0.98
MACD 0.02 0.15
Stochastic Oscillator 97.14 73.15

Price Performance

Historical Comparison
LOOP
NXTC

About LOOP Loop Industries Inc.

Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: